Valuation: Orion Oyj

Market Cap 11.49B 13.25B 10.76B 9.85B 18.59B 1,262B 18.83B 126B 49.42B 630B 49.73B 48.65B 2,098B P/E 2026 *
20.3x
P/E 2027 * 17.4x
Enterprise Value 11.4B 13.14B 10.68B 9.77B 18.44B 1,252B 18.68B 125B 49.03B 626B 49.34B 48.27B 2,082B EV / Sales 2026 *
5.44x
EV / Sales 2027 * 4.72x
Free-Float
90.5%
Yield 2026 *
2.38%
Yield 2027 * 2.66%
1 day+0.37%
1 week+1.49%
Current month+1.49%
1 month+14.39%
3 months+17.50%
6 months+10.98%
Current year+29.38%
1 week 79
Extreme 79
82.7
1 month 66.7
Extreme 66.7
82.7
Current year 62.3
Extreme 62.3
82.7
1 year 56.3
Extreme 56.3
82.7
3 years 32.5
Extreme 32.5
82.7
5 years 32.5
Extreme 32.5
82.7
10 years 24.75
Extreme 24.75
82.7
Manager TitleAgeSince
Chief Executive Officer 59 31/10/2022
Director of Finance/CFO 50 30/04/2024
Chief Operating Officer 46 31/12/2021
Director TitleAgeSince
Director/Board Member 63 21/03/2017
Director/Board Member 65 21/03/2017
Director/Board Member 66 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.37%+1.49% - - 13.25B
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+2.14%+5.49%+49.74%+40.83% 358B
+0.94%-0.06%+35.97%+40.81% 293B
+1.32%-4.84%+9.77%+10.42% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+4.35%+0.34%-0.42%-43.64% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +0.56%-1.90%+32.28%+51.49% 399.14B
Weighted average by Cap. +0.15%-0.83%+41.25%+78.35%

Financials

2026 *2027 *
Net sales 2.1B 2.42B 1.96B 1.8B 3.39B 230B 3.43B 22.97B 9.01B 115B 9.07B 8.87B 383B 2.37B 2.73B 2.22B 2.03B 3.83B 260B 3.88B 25.93B 10.17B 130B 10.24B 10.02B 432B
Net income 564M 650M 529M 484M 913M 61.96B 925M 6.18B 2.43B 30.96B 2.44B 2.39B 103B 660M 761M 618M 566M 1.07B 72.49B 1.08B 7.23B 2.84B 36.22B 2.86B 2.8B 121B
Net Debt -89.76M -103M -84.05M -76.88M -145M -9.85B -147M -983M -386M -4.92B -388M -380M -16.39B -333M -384M -312M -285M -538M -36.55B -545M -3.65B -1.43B -18.26B -1.44B -1.41B -60.78B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
07/08/26 81.90 +0.37% 2,054
06/08/26 €81.60 +0.25% 3,271
05/08/26 €81.40 +1.50% 11,066
04/08/26 €80.20 +1.26% 5,269
03/08/26 €79.20 -1.86% 3,533
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.60EUR
Average target price
76.67EUR
Spread / Average Target
-6.05%

Quarterly revenue - Rate of surprise